Date of Publication: 04-Mar-2026
INTELLIGENCE OVERVIEW
Agency: Health Sciences Authority – Singapore
The Health Sciences Authority (HSA), Singapore has released an updated guidance document titled “SG-HSA eCTD Specification and Guidance for Use Module 1 and Regional Information (Version 1.1)” on 4 March 2026. This update replaces Version 1.0 and introduces revised technical and regulatory requirements for electronic submissions in Singapore. The new specification will come into effect on 1 April 2026, after which applicants submitting regulatory dossiers in eCTD format must comply with the updated guidance.
The document provides detailed instructions on the structure, preparation, validation, and lifecycle management of eCTD submissions for therapeutic products in Singapore. The specification aligns with the international International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) eCTD version 3.2.2 standard, while outlining Singapore-specific requirements for Module 1 and regional information sections (2.3.R and 3.2.R). It also explains the hierarchical relationship between Application, Submission, and Sequence, which forms the backbone of lifecycle management in eCTD dossiers.
The updated guidance provides clarity on several technical aspects of dossier preparation, including application identification elements such as SG eCTD ID, application numbers, submission numbers, and sequence management. It also highlights important requirements related to validation processes, document navigation aids (bookmarks, hyperlinks, and table of contents), electronic signatures, and file format specifications. These measures are intended to improve dossier readability and support efficient evaluation by regulators.
Additionally, the guidance includes instructions on baseline submissions, lifecycle operations, reuse of files, and handling of multiple strengths, dosage forms, or presentations within a single application. Specific regulatory scenarios such as transfer of applications between applicants and management of pharmacovigilance submissions are also addressed. The document emphasizes the importance of validating eCTD sequences prior to submission and notes that errors in validation may lead to sequence rejection, reinforcing the need for robust dossier preparation practices.
Overall, the revised specification strengthens Singapore’s regulatory framework for electronic submissions and provides clearer technical guidance for applicants preparing therapeutic product dossiers. Pharmaceutical companies, regulatory affairs professionals, and software vendors involved in eCTD compilation and submission to HSA should review the updated document and ensure readiness for implementation before the 1 April 2026 effective date.
Industry Impact:
- Regulatory teams submitting dossiers to Singapore must update internal eCTD publishing processes to align with Version 1.1
- eCTD software vendors and publishing tools should ensure compatibility with the updated HSA validation and structure requirements
- Early adoption will help avoid validation errors, submission rejections, and regulatory delays after the new specification becomes effective
KEYWORDS: Lifecycle Management, eCTD, Dossier Lifecycle Operations
REFERENCE: https://file.go.gov.sg/sg-hsa-ectd-specification-v1-1.pdf https://www.hsa.gov.sg/therapeutic-products/register/ectd-submissions